Protease-induced immunoregulatory activity of platelet factor 4.
Intravenous injection of human or mouse serum or platelet material secreted from appropriately stimulated platelets ("releasate") together with antigen alleviates the immunosuppression in SJL/J mice induced by injection of irradiated lymphoma cells or in (CB6)F1 mice induced by injection of concanavalin A. We now report that injection of releasate from 10(6) human platelets restores plaque-forming cells to the unsuppressed number; greater amounts increase responses further. Immunoregulatory activity is released from platelets exposed to thrombin in parallel with other alpha-granule components. Heparin-agarose absorbs activity. Purified platelet factor 4 (PF4) has activity; beta-thromboglobulin and platelet-derived growth factor have little or none. Activity in serum is neutralized by goat anti-human PF4. An enzymatic step is necessary for production of immunoregulatory activity. Releasates boiled immediately after platelet aggregation with 250 nM A23187 or those produced by adding A23187 in the presence of 100 microM serine protease inhibitor (p-amidinophenyl)methanesulfonyl fluoride (APMSF) are ineffective, whereas releasates boiled or mixed with APMSF after incubation for 60 min are active. Activity is generated by incubating a mixture of heparin-absorbed releasate (as enzyme source) and heparin-agarose eluate of releasate made in the presence of APMSF (as substrate source). The enzymatic step does not alter the heparin-neutralizing activity of PF4. Apparently a secreted platelet protease converts PF4 to a form with immunoregulatory activity.
D000818:Animals; D000917:Antibody Formation; D001792:Blood Platelets / Q000502:physiology* / Q000648:ultrastructure; D002478:Cells, Cultured; D003594:Cytoplasmic Granules / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D006494:Heparin Antagonists; D006801:Humans; D051379:Mice; D010447:Peptide Hydrolases / Q000378:metabolism; D010978:Platelet Factor 4 / Q000502:physiology*; D011480:Protease Inhibitors / Q000494:pharmacology
D006494:Heparin Antagonists; D011480:Protease Inhibitors; D010978:Platelet Factor 4; D010447:Peptide Hydrolases